Robeco Institutional Asset Management B.V. Has $56.51 Million Stock Position in Exelixis, Inc. $EXEL

Key Points

• Robeco Institutional Asset Management boosted its position in Exelixis by 31.5% in Q4 and now owns 1,289,291 shares worth $56.51 million, representing about 0.48% of the company.
• Company insiders have been net sellers recently — including SVP Brenda Hefti and CFO Christopher Senner — with insiders offloading 362,849 shares valued at roughly $15.9 million over the last 90 days, leaving insiders with 2.85% ownership.
• Analysts are mixed: the consensus rating is Hold with a $46.94 target, while recent results showed an EPS beat ($0.94 vs. $0.74) but slightly missed revenue, and the stock trades near $45 with a roughly $11.7 billion market cap.

Robeco Institutional Asset Management B.V. lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 31.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,289,291 shares of the biotechnology company's stock after purchasing an additional 309,046 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.48% of Exelixis worth $56,510,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Richardson Financial Services Inc. grew its holdings in shares of Exelixis by 95.1% during the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 292 shares in the last quarter. Anchor Investment Management LLC grew its holdings in shares of Exelixis by 500.0% during the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 500 shares in the last quarter. Root Financial Partners LLC acquired a new stake in shares of Exelixis during the 3rd quarter worth $28,000. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Exelixis by 1,380.4% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 773 shares in the last quarter. Finally, V Square Quantitative Management LLC acquired a new stake in shares of Exelixis during the 4th quarter worth $44,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Brenda Hefti sold 18,669 shares of the firm's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total value of $821,622.69. Following the sale, the senior vice president directly owned 96,512 shares of the company's stock, valued at $4,247,493.12. This trade represents a 16.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Christopher J. Senner sold 30,617 shares of Exelixis stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $43.67, for a total value of $1,337,044.39. Following the sale, the chief financial officer directly owned 976,092 shares in the company, valued at $42,625,937.64. The trade was a 3.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 362,849 shares of company stock valued at $15,917,463 over the last ninety days. 2.85% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on EXEL. Morgan Stanley increased their target price on Exelixis from $48.00 to $49.00 and gave the stock an "equal weight" rating in a report on Monday, February 2nd. HC Wainwright increased their target price on Exelixis from $52.00 to $54.00 and gave the stock a "buy" rating in a report on Thursday, February 12th. Citigroup lowered Exelixis from a "market outperform" rating to an "underperform" rating in a report on Monday, January 5th. Bank of America lowered Exelixis from a "neutral" rating to an "underperform" rating and set a $41.00 target price on the stock. in a report on Monday, January 5th. Finally, Weiss Ratings reissued a "buy (b)" rating on shares of Exelixis in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Exelixis has a consensus rating of "Hold" and a consensus price target of $46.94.

Exelixis Stock Up 1.6%

NASDAQ:EXEL opened at $44.96 on Tuesday. The stock's 50-day simple moving average is $42.89 and its 200 day simple moving average is $42.34. The firm has a market capitalization of $11.68 billion, a PE ratio of 16.23, a price-to-earnings-growth ratio of 0.99 and a beta of 0.42. Exelixis, Inc. has a twelve month low of $33.76 and a twelve month high of $49.62.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.20. The business had revenue of $598.66 million for the quarter, compared to analyst estimates of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.Exelixis's revenue was up 5.6% compared to the same quarter last year. During the same period last year, the firm posted $0.55 earnings per share. On average, analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.